AUS
NZ
UK
CA
USA
IND
Highlights
- GENinCode partners with Genesupport SA to expand ROCA® Test availability across Switzerland.
- The ROCA Test, recommended by NICE in March 2024, is designed for women at high risk of ovarian cancer.
- The collaboration will support over 11,000 women in Switzerland, focusing on those with BRCA gene mutations.
GENinCode Plc (LSE:GENI), a UK-based predictive genetics company focused on preventing cardiovascular disease and ovarian cancer risk, has announced a partnership with Genesupport SA, part of the Sonic Switzerland network of laboratories. This collaboration aims to make the ROCA® Test more widely available in Switzerland, allowing women at high risk for ovarian cancer (OC) to access advanced screening.
In March 2024, the ROCA Test received a recommendation from the National Institute for Health and Care Excellence (NICE) as the preferred method for ovarian cancer surveillance in high-risk individuals who wish to defer risk-reducing surgery. Following this milestone, Genesupport SA will offer the ROCA Test through all Sonic Switzerland diagnostic and genetic companies, including Genesupport, Medigenome Medisupport, Medica, Medisyn, and Dr. Risch. These companies cover major Swiss cities such as Geneva, Lausanne, Bern, and Zurich, along with regional centers in St. Gallen, Zug, Lucerne, and Lugano/Locarno.
The ROCA Test will be available to women who are BRCA positive and have not undergone risk-reducing surgery, supporting a population of over 11,000 women at high risk for ovarian cancer. Genesupport's network is also affiliated with key tumor centers and hospitals across Switzerland, such as Hirslanden and the Swiss Medical Network, making the test accessible to a wide demographic.
Ovarian cancer (OC) remains a leading cause of cancer-related death globally, with over 300,000 new cases reported annually. Early detection significantly improves treatment outcomes, and the ROCA Test offers a crucial tool for identifying the disease in its earlier, more treatable stages. The test uses a proprietary algorithm that calculates an individual’s OC risk, considering factors like age and CA-125 blood test results. The test has been clinically evaluated through numerous prospective studies, demonstrating its high accuracy and ability to detect ovarian cancer at earlier stages.
